 |
245 Diseases |  |
389 Trials |
|
389 Trials |  |
11400 News |  |
| «12...128129130131132133134135136137138...143144» |
- Erbitux (cetuximab) / Eli Lilly, EMD Serono
Enrollment closed: Nab-Paclitaxel, Cetuximab, Cisplatin, and Radiation Therapy in Treating Patients With Recurrent Head and Neck Cancer (clinicaltrials.gov) - May 11, 2014
P2, N=50, Active, not recruiting, Sponsor: University of Texas Southwestern Medical Center
Completed --> Active, not recruiting
- tivantinib (ARQ 197) / Daiichi Sankyo, Kyowa Kirin, Merck (MSD)
Trial primary completion date: An Extension Protocol for Subjects Who Were Previously Enrolled in Other Tivantinib (ARQ 197) Protocols (clinicaltrials.gov) - May 8, 2014
P1/2, N=50, Enrolling by invitation, Sponsor: ArQule
Completed --> Active, not recruiting Trial primary completion date: Jun 2014 --> Dec 2016
- tivantinib (ARQ 197) / Daiichi Sankyo, Kyowa Kirin, Merck (MSD)
Trial completion date: An Extension Protocol for Subjects Who Were Previously Enrolled in Other Tivantinib (ARQ 197) Protocols (clinicaltrials.gov) - May 8, 2014
P1/2, N=50, Enrolling by invitation, Sponsor: ArQule
Trial primary completion date: Jun 2014 --> Dec 2016 Trial completion date: Jun 2014 --> Dec 2016
- ||| Erbitux (cetuximab) / Eli Lilly, EMD Serono, urelumab (BMS-663513) / BMS, Ono Pharma
Enrollment open, Combination therapy, Metastases: Combination Study of Urelumab and Cetuximab in Patients With Advanced/Metastatic Colorectal Cancer or Advanced/Metastatic Head and Neck Cancer (clinicaltrials.gov) - May 8, 2014
P1, N=104, Recruiting, Sponsor: Bristol-Myers Squibb
Trial completion date: Jun 2014 --> Dec 2016 Not yet recruiting --> Recruiting
- Erbitux (cetuximab) / Eli Lilly, EMD Serono
Trial primary completion date: A Study With Neoadjuvant mFOLFOX7 Plus Cetuximab to Determine the Surgical Conversion Rate for Unresectable Colorectal Cancer With Metastases Confined to the Liver (clinicaltrials.gov) - May 6, 2014
P2, N=20, Active, not recruiting, Sponsor: National Surgical Adjuvant Breast and Bowel Project (NSABP)
Not yet recruiting --> Recruiting Trial primary completion date: Jun 2013 --> Jul 2013
- ||||| Opdivo (nivolumab) / BMS
Trial initiation date, Metastases: Trial of Nivolumab vs Therapy of Investigator's Choice in Recurrent or Metastatic Head and Neck Carcinoma (CheckMate 141) (clinicaltrials.gov) - May 6, 2014
P3, N=180, Recruiting, Sponsor: Bristol-Myers Squibb
Trial primary completion date: Jun 2013 --> Jul 2013 Initiation date: Apr 2014 --> May 2014
- Erbitux (cetuximab) / Eli Lilly, EMD Serono
Trial completion date: A Study With Neoadjuvant mFOLFOX7 Plus Cetuximab to Determine the Surgical Conversion Rate for Unresectable Colorectal Cancer With Metastases Confined to the Liver (clinicaltrials.gov) - May 6, 2014
P2, N=20, Active, not recruiting, Sponsor: National Surgical Adjuvant Breast and Bowel Project (NSABP)
Initiation date: Apr 2014 --> May 2014 Trial completion date: Jan 2018 --> Dec 2015
- Erbitux (cetuximab) / Eli Lilly, EMD Serono
Enrollment closed, Surgery, Metastases: EMR 622022237: Neo-adjuvant Erbitux-based Chemotherapy for Locally Advanced Oral/Oropharyngeal Cancer (clinicaltrials.gov) - May 6, 2014
P2, N=115, Active, not recruiting, Sponsor: Shanghai Jiao Tong University School of Medicine
Trial completion date: Jan 2018 --> Dec 2015 Recruiting --> Active, not recruiting
- Erbitux (cetuximab) / Eli Lilly, EMD Serono
Trial completion date: Pre-operation Chemo and Antibody Therapy Followed by Surgical Resection and Adjuvant Chemoradiation for Gastric Cancer (clinicaltrials.gov) - May 6, 2014
P2, N=30, Active, not recruiting, Sponsor: New York University School of Medicine
Recruiting --> Active, not recruiting Trial completion date: Mar 2014 --> Dec 2014
- Erbitux (cetuximab) / Eli Lilly, EMD Serono
Trial completion date, Metastases: Cetuximab Plus Biweekly Capecitabine and Oxaliplatin in KRAS Wild Type Metastatic Colorectal Cancer (clinicaltrials.gov) - May 6, 2014
P2, N=39, Active, not recruiting, Sponsor: New York University School of Medicine
Trial completion date: Mar 2014 --> Dec 2014 Trial completion date: Aug 2013 --> Oct 2014
- Avastin (bevacizumab) / Roche, Erbitux (cetuximab) / Eli Lilly, EMD Serono
Trial primary completion date, Combination therapy, Surgery: SWOG-ECOG-E2204: Bevacizumab or Cetuximab And Gemcitabine Hydrochloride, Capecitabine, and Radiation Therapy in Treating Patients With Pacreatic Cancer That Has Been Completely Removed By Surgery (clinicaltrials.gov) - May 5, 2014
P2, N=137, Completed, Sponsor: National Cancer Institute (NCI)
Trial completion date: Aug 2013 --> Oct 2014 Trial primary completion date: Jan 2013 --> Jul 2008
- Avastin (bevacizumab) / Roche, Erbitux (cetuximab) / Eli Lilly, EMD Serono
Trial completion date, Combination therapy, Surgery: SWOG-ECOG-E2204: Bevacizumab or Cetuximab And Gemcitabine Hydrochloride, Capecitabine, and Radiation Therapy in Treating Patients With Pacreatic Cancer That Has Been Completely Removed By Surgery (clinicaltrials.gov) - May 5, 2014
P2, N=137, Completed, Sponsor: National Cancer Institute (NCI)
Trial primary completion date: Jan 2013 --> Jul 2008 Trial completion date: Jan 2013 --> Feb 2012
- |||| duligotuzumab (MEHD7945A) / Roche
Enrollment open, Metastases: A Study of MEHD7945A Versus Cetuximab in Patients With Recurrent/Metastatic Squamous Cell Carcinoma of The Head And Neck (clinicaltrials.gov) - May 4, 2014
P2, N=110, Recruiting, Sponsor: Genentech
Trial completion date: Jan 2013 --> Feb 2012 Active, not recruiting --> Recruiting
- || Avastin (bevacizumab) / Roche, Erbitux (cetuximab) / Eli Lilly, EMD Serono
Trial primary completion date, Metastases: Radiation, Cetuximab and Pemetrexed With or Without Bevacizumab in Locally Advanced Head and Neck Cancer (clinicaltrials.gov) - May 4, 2014
P2, N=80, Active, not recruiting, Sponsor: University of Pittsburgh
Active, not recruiting --> Recruiting Trial primary completion date: Jul 2013 --> Sep 2014
- || Avastin (bevacizumab) / Roche, Erbitux (cetuximab) / Eli Lilly, EMD Serono
Trial completion date, Metastases: Radiation, Cetuximab and Pemetrexed With or Without Bevacizumab in Locally Advanced Head and Neck Cancer (clinicaltrials.gov) - May 4, 2014
P2, N=80, Active, not recruiting, Sponsor: University of Pittsburgh
Trial primary completion date: Jul 2013 --> Sep 2014 Trial completion date: Dec 2013 --> Sep 2014
- Avastin (bevacizumab) / Roche, Erbitux (cetuximab) / Eli Lilly, EMD Serono
Trial completion date, Metastases: Combination of Cetuximab, Capecitabine, and Oxaliplatin With or Without Bevacizumab (clinicaltrials.gov) - May 4, 2014
P2, N=23, Terminated, Sponsor: Fox Chase Cancer Center
Trial completion date: Dec 2013 --> Sep 2014 Trial completion date: Dec 2012 --> Dec 2013
- ||| Avastin (bevacizumab) / Roche, Erbitux (cetuximab) / Eli Lilly, EMD Serono
Enrollment closed, Metastases: Radiation, Cetuximab and Pemetrexed With or Without Bevacizumab in Locally Advanced Head and Neck Cancer (clinicaltrials.gov) - May 4, 2014
P2, N=80, Active, not recruiting, Sponsor: University of Pittsburgh
Trial completion date: Dec 2012 --> Dec 2013 Recruiting --> Active, not recruiting
- |||||| Opdivo (nivolumab) / BMS
Enrollment open, Metastases: Trial of Nivolumab vs Therapy of Investigator's Choice in Recurrent or Metastatic Head and Neck Carcinoma (CheckMate 141) (clinicaltrials.gov) - May 4, 2014
P3, N=180, Recruiting, Sponsor: Bristol-Myers Squibb
Recruiting --> Active, not recruiting Not yet recruiting --> Recruiting
- Erbitux (cetuximab) / Eli Lilly, EMD Serono
Trial termination, Metastases: Cetuximab, 5-FU and Radiation as Neoadjuvant Therapy for Patients With Locally Advanced Rectal Cancer (clinicaltrials.gov) - Apr 29, 2014
P2, N=13, Terminated, Sponsor: Dana-Farber Cancer Institute
Not yet recruiting --> Recruiting Recruiting --> Terminated; Slow accrual
- Erbitux (cetuximab) / Eli Lilly, EMD Serono
Enrollment change, Metastases: Cetuximab, 5-FU and Radiation as Neoadjuvant Therapy for Patients With Locally Advanced Rectal Cancer (clinicaltrials.gov) - Apr 29, 2014
P2, N=13, Terminated, Sponsor: Dana-Farber Cancer Institute
Recruiting --> Terminated; Slow accrual N=25 --> 13
- | Erbitux (cetuximab) / Eli Lilly, EMD Serono
Biomarker, New P2 trial, Metastases: Radiotherapy With Cisplatin vs. Docetaxel-cetuximab in HNSCC: ERCC1 Biomarker Enrichment and Interaction Design (clinicaltrials.gov) - Apr 28, 2014
P2, N=160, Recruiting, Sponsor: University of Pittsburgh
- |||||| Avastin (bevacizumab) / Roche, Erbitux (cetuximab) / Eli Lilly, EMD Serono, Vectibix (panitumumab) / Amgen
Enrollment open, Metastases: STRATEGIC-1: Multi-Line Therapy Trial in Unresectable Metastatic Colorectal Cancer (clinicaltrials.gov) - Apr 28, 2014
P3, N=474, Recruiting, Sponsor: Groupe Cooperateur Multidisciplinaire en Oncologie (GERCOR)
N=25 --> 13 Not yet recruiting --> Recruiting
- Erbitux (cetuximab) / Eli Lilly, EMD Serono
Trial primary completion date, Surgery: Immune Response on Neoadjuvant Therapy in Non-small-cell Lung Cancer (NSCLC) (clinicaltrials.gov) - Apr 27, 2014
P2, N=41, Completed, Sponsor: Wolfgang Hilbe
Not yet recruiting --> Recruiting Trial primary completion date: Aug 2010 --> Jun 2011
- | Erbitux (cetuximab) / Eli Lilly, EMD Serono
Trial completion, Surgery: Immune Response on Neoadjuvant Therapy in Non-small-cell Lung Cancer (NSCLC) (clinicaltrials.gov) - Apr 27, 2014
P2, N=41, Completed, Sponsor: Wolfgang Hilbe
Trial primary completion date: Aug 2010 --> Jun 2011 Active, not recruiting --> Completed
- ||| prexasertib (ACR-368) / Acrivon Therap
New P1 trial, Combination therapy, Metastases: A Study of Prexasertib (LY2606368) With Chemotherapy or Targeted Agents in Participants With Advanced Cancer (clinicaltrials.gov) - Apr 24, 2014
P1, N=70, Not yet recruiting, Sponsor: Eli Lilly and Company
- Erbitux (cetuximab) / Eli Lilly, EMD Serono
New P2 trial, Metastases: Weekly Carboplatin, Paclitaxel and Cetuximab Treatment for Patients With Recurrent or Metastatic SCCHN (clinicaltrials.gov) - Apr 23, 2014
P2, N=38, Recruiting, Sponsor: UNC Lineberger Comprehensive Cancer Center
- | Erbitux (cetuximab) / Eli Lilly, EMD Serono, Opdivo (nivolumab) / BMS, motolimod (VTX 2337) / BMS
Biomarker, New P1 trial, PD(L)-1 Biomarker: A Phase Ib Study of Neoadjuvant of Cetuximab Plus Motolimod and Cetuximab Plus Motolimod Plus Nivolumab (clinicaltrials.gov) - Apr 21, 2014
P1, N=15, Not yet recruiting, Sponsor: VentiRx Pharmaceuticals Inc.
- | Erbitux (cetuximab) / Eli Lilly, EMD Serono
New P1/2 trial, Metastases: IMPACT-CRC: Image Guided Treatment Optimization With Cetuximab for Patients With Metastatic Colorectal Cancer (clinicaltrials.gov) - Apr 17, 2014
P1/2, N=85, Not yet recruiting, Sponsor: VU University Medical Center
- Erbitux (cetuximab) / Eli Lilly, EMD Serono
Biomarker, Circulating tumor cells, Tumor cell, Metastases: CIRCUTEC: Circulating Tumor Cells as an Early Predictive head-and -Neck Squamous-cell Carcinoma (clinicaltrials.gov) - Apr 17, 2014
P=N/A, N=115, Recruiting, Sponsor: University Hospital, Montpellier
- ||||| Vectibix (panitumumab) / Amgen
Enrollment change, Metastases: ASPECCT: A Study of Panitumumab Efficacy and Safety Compared to Cetuximab in Patients With KRAS Wild-Type Metastatic Colorectal Cancer (clinicaltrials.gov) - Apr 14, 2014
P3, N=1010, Active, not recruiting, Sponsor: Amgen
Active, not recruiting --> Completed N=1418 --> 1010
- | Erbitux (cetuximab) / Eli Lilly, EMD Serono
Biomarker, New P2 trial, Metastases: Changes in Tumor Tissue and Serum Biomarkers Before and After Cetuximab Combined With Preoperative Radiotherapy in Locally Advanced Thoracic Esophageal Squamous Cell Carcinoma (clinicaltrials.gov) - Apr 12, 2014
P2, N=100, Recruiting, Sponsor: Sichuan Cancer Hospital and Research Institute
- ||| Erbitux (cetuximab) / Eli Lilly, EMD Serono, urelumab (BMS-663513) / BMS, Ono Pharma
New P1 trial, Combination therapy, Metastases: Combination Study of Urelumab and Cetuximab in Patients With Advanced/Metastatic Colorectal Cancer or Advanced/Metastatic Head and Neck Cancer (clinicaltrials.gov) - Apr 8, 2014
P1, N=104, Not yet recruiting, Sponsor: Bristol-Myers Squibb
- || lumretuzumab (RG7116) / Roche
Enrollment change, Combination therapy, Metastases: A Study of RO5479599 Alone or in Combination With Cetuximab or Erlotinib in Participants With Metastatic and/or Locally Advanced Malignant Human Epidermal Growth Factor Receptor (HER3) Expressing Solid Tumors of Epithelial Cell Origin (clinicaltrials.gov) - Apr 7, 2014
P1, N=160, Recruiting, Sponsor: Hoffmann-La Roche
N=1418 --> 1010 N=105 --> 160
- | Erbitux (cetuximab) / Eli Lilly, EMD Serono
Trial completion, Metastases: Evaluation of Cetuximab (ERBITUX) and Concurrent Carboplatin, Paclitaxel & Radiotherapy in the Management of Patients With Advanced Locoregional Squamous Cell Carcinomas of the Head and Neck (GCC 0442) (clinicaltrials.gov) - Apr 6, 2014
P2, N=43, Completed, Sponsor: Department of Radiation Oncology
N=105 --> 160 Active, not recruiting --> Completed
- ||| Erbitux (cetuximab) / Eli Lilly, EMD Serono
Trial completion date, Combination therapy, Metastases: EMR 62240-506: Trial With Cetuximab in Maintenance Therapy After Platinum Based Chemotherapy in First Line Treatment of Non-small Cell Lung Cancer (NSCLC) (clinicaltrials.gov) - Apr 3, 2014
P3, N=583, Completed, Sponsor: Merck KGaA
Active, not recruiting --> Completed Trial completion date: Dec 2012 --> Jun 2013
- ||||||| Erbitux (cetuximab) / Eli Lilly, EMD Serono
Trial completion, Combination therapy, Metastases: EMR 62240-506: Trial With Cetuximab in Maintenance Therapy After Platinum Based Chemotherapy in First Line Treatment of Non-small Cell Lung Cancer (NSCLC) (clinicaltrials.gov) - Apr 3, 2014
P3, N=583, Completed, Sponsor: Merck KGaA
Trial completion date: Dec 2012 --> Jun 2013 Active, not recruiting --> Completed
- |||||||||| Opdivo (nivolumab) / BMS
New P3 trial, Metastases: Trial of Nivolumab vs Therapy of Investigator's Choice in Recurrent or Metastatic Head and Neck Carcinoma (CheckMate 141) (clinicaltrials.gov) - Apr 3, 2014
P3, N=180, Not yet recruiting, Sponsor: Bristol-Myers Squibb
- | Erbitux (cetuximab) / Eli Lilly, EMD Serono
Enrollment change, Metastases: Study of Sorafenib/Cetuximab in Head and Neck Cancer (clinicaltrials.gov) - Apr 1, 2014
P1/2, N=31, Completed, Sponsor: Duke University
Active, not recruiting --> Completed N=43 --> 31
- | Erbitux (cetuximab) / Eli Lilly, EMD Serono
Trial completion, Metastases: Study of Sorafenib/Cetuximab in Head and Neck Cancer (clinicaltrials.gov) - Apr 1, 2014
P1/2, N=31, Completed, Sponsor: Duke University
N=43 --> 31 Active, not recruiting --> Completed
- Ibrance (palbociclib) / Pfizer, Erbitux (cetuximab) / Eli Lilly, EMD Serono
New P1/2 trial: PD 0332991 and Cetuximab in Patients With Incurable SCCHN (clinicaltrials.gov) - Mar 30, 2014
P1/2, N=42, Not yet recruiting, Sponsor: Washington University School of Medicine
- ||| Zelboraf (vemurafenib) / Roche
Enrollment change: A Study of Vemurafenib in Participants With BRAF V600 Mutation-Positive Cancers (clinicaltrials.gov) - Mar 26, 2014
P2, N=160, Recruiting, Sponsor: Hoffmann-La Roche
Active, not recruiting --> Completed N=101 --> 160
- Erbitux (cetuximab) / Eli Lilly, EMD Serono
Trial initiation date, Metastases: Cetuximab Compared to Mitomycin-C and 5-Fluorouracil for Locally Advanced Squamous Cell Carcinomas of the Head and Neck (clinicaltrials.gov) - Mar 23, 2014
P4, N=70, Not yet recruiting, Sponsor: Medical University Innsbruck
N=101 --> 160 Initiation date: Jan 2014 --> Apr 2014
- Erbitux (cetuximab) / Eli Lilly, EMD Serono
Enrollment change, Metastases: Chemoradiation Plus Weekly c225 Against Locoregionally Advanced Nasopharyngeal Carcinoma (NPC) (clinicaltrials.gov) - Mar 20, 2014
P1/2, N=61, Completed, Sponsor: Jiangsu Cancer Institute & Hospital
Initiation date: Jan 2014 --> Apr 2014 N=50 --> 61
- Erbitux (cetuximab) / Eli Lilly, EMD Serono, Stivarga (regorafenib) / Bayer
New P1 trial, Metastases: Regorafenib and Cetuximab in Patients With Advanced Malignancy (clinicaltrials.gov) - Mar 20, 2014
P1, N=83, Recruiting, Sponsor: M.D. Anderson Cancer Center
- Erbitux (cetuximab) / Eli Lilly, EMD Serono
Trial completion, Metastases: Chemoradiation Plus Weekly c225 Against Locoregionally Advanced Nasopharyngeal Carcinoma (NPC) (clinicaltrials.gov) - Mar 20, 2014
P1/2, N=61, Completed, Sponsor: Jiangsu Cancer Institute & Hospital
N=50 --> 61 Recruiting --> Completed
- Erbitux (cetuximab) / Eli Lilly, EMD Serono
Enrollment closed, Combination therapy: Intra-hepatic Chemotherapy in Patient With Non-resectable Liver Metastases From Cholangiocarcinoma (clinicaltrials.gov) - Mar 19, 2014
P2, N=100, Active, not recruiting, Sponsor: Dorte Nielsen
Recruiting --> Completed Recruiting --> Active, not recruiting
- | Erbitux (cetuximab) / Eli Lilly, EMD Serono
Trial completion: Assessment of the Efficacy of a Neoadjuvant Combination: "Chemotherapy-targeted Therapy" in Breast Cancer. (clinicaltrials.gov) - Mar 18, 2014
P2, N=35, Completed, Sponsor: Centre Jean Perrin
Recruiting --> Active, not recruiting Recruiting --> Completed
- | Erbitux (cetuximab) / Eli Lilly, EMD Serono
Trial completion, Metastases: Cetuximab in Patients With Unresectable or Metastatic Hepatocellular Carcinoma (clinicaltrials.gov) - Mar 15, 2014
P2, N=30, Completed, Sponsor: Massachusetts General Hospital
Recruiting --> Completed Active, not recruiting --> Completed
- cixutumumab (IMC A12) / Eli Lilly, Avastin (bevacizumab) / Roche, Erbitux (cetuximab) / Eli Lilly, EMD Serono
Enrollment change, Combination therapy, Metastases: Carboplatin and Paclitaxel Combined With Cetuximab and/or IMC-A12 in Patients With Advanced Non-Small Cell Lung Cancer (clinicaltrials.gov) - Mar 12, 2014
P2, N=140, Active, not recruiting, Sponsor: National Cancer Institute (NCI)
Active, not recruiting --> Completed N=200 --> 140
- Erbitux (cetuximab) / Eli Lilly, EMD Serono, buparlisib (AN2025) / Novartis, Adlai Nortye
Biomarker, Enrollment open, Combination therapy, Metastases: PI3K Inhibitor BKM120 and Cetuximab in Treating Patients With Recurrent or Metastatic Head and Neck Cancer (clinicaltrials.gov) - Mar 10, 2014
P1/2, N=30, Recruiting, Sponsor: University of Chicago
N=200 --> 140 Not yet recruiting --> Recruiting